An FGFR inhibitor (IC50 = 1.9 nM); reduces FGF2-induced endothelial cell proliferation and migration (IC50s = 31 and 15.2 nM, respectively); reduces proliferation of cells expressing FGFR1-4 at 100 nM; reduces disease severity and enhances physical performance in a mouse model of arthritis at 30 mg/kg per day; reduces tumor growth and metastasis in a Panc02 mouse orthotopic tumor model; reduces atherosclerotic lesion size in the aortic sinus of apoE-/- mice at 50 mg/kg per day; reduces intimal hyperplasia following jugular vein-to-artery bypass grafting surgery in rats,